4月2日 - ** 药物开发商AllakosALLK.O的股票盘前上涨45.6%，达到32美分
**Concentra Biosciences将 以每股33美分的现金收购Allakos ，比ALLK上次收盘价溢价52%。
** Allakos表示，Concentra的一家全资子公司将在4月15日前开始要约收购ALLK的所有流通股。
** 公司预计交易将于 2025 年 5 月完成
** 称交易的完成取决于交易完成时至少3550万美元现金的可用性，以及其他惯例成交条件
** 该公司股价年累计下跌 82.1%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.